Abstract
Dynamic early-phase PET images acquired with radiotracers binding to fibrillar amyloid-beta (Aβ) have shown to correlate with [18F]fluorodeoxyglucose (FDG) PET images and provide perfusion-like information. Perfusion information of static PET scans acquired during the first minute after radiotracer injection (FMF, first-minute-frame) is compared to [18F]FDG PET images. FMFs of 60 patients acquired with [18F]florbetapir (FBP), [18F]flutemetamol (FMM), and [18F]florbetaben (FBB) are compared to [18F]FDG PET images. Regional standardized uptake value ratios (SUVR) are directly compared and intrapatient Pearson’s correlation coefficients are calculated to evaluate the correlation of FMFs to their corresponding [18F]FDG PET images. Additionally, regional interpatient correlations are calculated. The intensity profiles of mean SUVRs among the study cohort (r = 0.98, p < 0.001) and intrapatient analyses show strong correlations between FMFs and [18F]FDG PET images (r = 0.93 ± 0.05). Regional VOI-based analyses also result in high correlation coefficients. The FMF shows similar information to the cerebral metabolic patterns obtained by [18F]FDG PET imaging. Therefore, it could be an alternative to the dynamic imaging of early phase amyloid PET and be used as an additional neurodegeneration biomarker in amyloid PET studies in routine clinical practice while being acquired at the same time as amyloid PET images.
Highlights
Three main biomarkers have been established for the diagnosis of Alzheimer’s disease (AD): (1) biomarkers of amyloid-beta (Aβ) plaques; (2) biomarkers of fibrillar tau; and (3) biomarkers of neurodegeneration [1]
The aim of this study is to quantitatively evaluate the perfusion information of static brain amyloid PET images obtained in the first minute after radiotracer injection, hereafter called FMFs, with 18 F- labeled radiotracers, compared to the cerebral metabolism as measured in [18 F]FDG PET images
Fourteen subjects were clinically classified as having mild cognitive impairment (MCI) and 36 patients with dementia, in which 16 of them classified as having dementia probably due to AD and 20 with dementia possibly due to AD, based on [47]
Summary
Three main biomarkers have been established for the diagnosis of Alzheimer’s disease (AD): (1) biomarkers of amyloid-beta (Aβ) plaques; (2) biomarkers of fibrillar tau; and (3) biomarkers of neurodegeneration [1]. Abnormal extracellular Aβ deposition leads to neuronal death and, impaired cognitive functions [2]. PET imaging allows for the in vivo evaluation of the deposition of Aβ plaques. Neuronal impairment and decreased neuronal activity results in reduced brain metabolism [7]. [18 F]fluorodeoxyglucose (FDG) is currently widely used for the imaging of brain metabolism and the diagnosis of neurodegenerative diseases. Brain [18 F]FDG PET is regarded as a good biomarker of neurodegeneration in AD [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
